Zhongbao Pharmaceuticals launched the world's first phase III clinical trial of the new class 1.1 drug Sulfate Shuxin

Group leader unit Professor Guo Jihong of Peking University People's Hospital, special expert Professor Yang Yanmin of Beijing's Outer Cardiovascular Hospital, Professor Zhu Jun, Vice President of Hangzhou Taige Pharmaceutical Technology Co., Ltd. Mr. Wu Qiang and the core team members of Yangzhou Zhongbao Pharmaceutical Co., Ltd. jointly launched the phase III clinical study of Sulphuric acid Shuxin!The successful convening of this meeting marked the official launch of the validated clinical phase III study of sulfate sulphate for laboratory-based early fights. Zhang Guanya, chairman of
Zhongbao Pharmaceuticals, said: "It is well known that there has been no safe and effective market for innovative drugs in the field of arrhythmia for nearly three decades, and we are honored to be able to participate and witness this process as the clinical trials of sulfate shuxinin carry the expectations of many clinical experts and patients."
" Guo Jihong, deputy director of cardiology at Peking University People's Hospital, said at the meeting: "The study of sulfate Shuxin sulfate has lasted several years, brought together the efforts of many researchers, pharmacological innovation has been widely recognized, safety has also been consistently confirmed in the early trials, oral tablet research and development success and long-term clinical use of drugs, will be serious arrhyth arrhythmic and arrhythmic caused by the progress of the disease has played a significant preventive and therapeutic effect."
" room arrhyth arrhythmic and cervial early arrhythmic includes cervical early beat (referred to as room early), non-persistent and persistent cerviatic taffeia (room rate), atrial throbbing (room throbbing) and atrial fibrillation (room tremor).
and ion channel disease are common causes of arrhythmics, but they are not uncommon in patients without structural heart disease.
clinical manifestations of laboratory arrhyth arrhythmics vary widely, can be asymptomatic, can also cause hemodynamic disorders, and even sudden cardiac death.
of the hospital confirmed that the total number of Chinese mainland deaths in the hospital reached 544,000.
in recent years, it has been clearly combined with patients with methic heart disease, especially those with ishemosis and cardiac insequitation, which has prognostic significance and should be used as the basis for clinical treatment.
cular early arrest (or pre-lysal contraction), referred to as chamber early, refers to his bundle and sub-branch of the anteriocardial excitable cooker pre-excitable pre-dation, is the most common clinical arrhythmic, its occurrence of a wide range of people, including normal healthy population and a variety of heart patients.
most common symptoms include palpitations, chest tightness, and cardiac arrest.
is the most common clinical arrhyth arrhythmic, which occurs in a wide range of populations, including normal healthy people and patients with various heart diseases.
in the general population, the incidence rate is about 1% to 4%.
a survey of the general population found that the early prevalence rate of the room detected by the ordinary 12-conducting electroctogram was 1%, while the rate of laboratory early detection through the 24h or 48h dynamic electrostatgram was as high as 40% to 75%.
incidence of the laboratory increases gradually with age, with a rate of 1 per cent among children aged 11 years, compared with 69 per cent among those aged 75.
all kinds of mesocardial heart disease such as coronary heart disease, cardiomyopathy, valve heart disease, diaphragm prodressing, etc. are common causes in the room.
is of great significance to relieve symptoms, improve prognostics and ensure the safety of patients' lives by taking reasonable treatment methods in time for the laboratory-like early fight of combinator-quality heart disease.
anti-arrhythmic drug Anti-arrhythmic drug is usually used by the improved Vaughan Williams classification method, according to the different electrophysiological effects of the drug, divided into sodium channel blockers (I.a, I.b and I.c), β organic blockers (CLASS II.), potassium channel blockers (Class III. class), calcium channel blockers (IV. class) four categories.
Sulphuric acid Shuxin sulfuric acid Shuxin is a natural product Changshan alkali b as the structural guide for the full synthesis of the compound, is a multi-ion channel blocker, inhibits myocardial cell sodium, potassium and calcium channels, play a compound multi-ion channel blocking effect, achieve anti-arrhythmic effect, the experimental arrhythmic model has significant effect, and this mechanism can make clinical application more safe, for China has independent intellectual property rights of the original new drug.
From the pharmacological mechanism of action, sulfate shuxin from the binding point of the heart sodium channel is much faster than the hydrochloric acid mesi law, in terms of INa, F blocking effect, sulfate sulfate shuxin shows class Ib properties, and L-type calcium ion flow lack of significant effect, can be used with β epinephrine blockers.
in clinical applications, sulfate sulphate exhibits a very low risk of cutting-edge torsional arrhyth arrhythmics (Tdep Risk), which has no arrhyth arrhythmic effect.
at concentrations of up to 100μM, sulfate sulphate does not reverse positive step contraction and does not significantly inhibit L-type calcium current; In preclinical studies using rabbit chamber wedge preparations, sulfate sulphate does not produce arrhythmic disorders and does not significantly increase contraction.
phase II clinical trials, sulfate sulphate did not increase baseline sinus heart rate, nor did it shorten the PR interstitium in individuals.
results of several studies have shown that sulphate sulphate can be combined with basic therapy for laboratory early-beat therapy in patients with coronary heart disease and/or heart failure.
2015, Zhongbao Pharmaceuticals was granted exclusive licensing rights within the scope of the Chinese mainland of the Chinese Academy of Sciences' Shanghai Pharmaceutical Institute of Sulfate Shuxin.
it is understood that the preclinical study of Zhongbao Pharmaceuticals has been completed and is now in preparation for IND declaration, with a plan to start clinical Phase I trials in the second quarter of 2021.
Conference Site The participating researchers and the clinical team of Zhongbao Pharmaceutical Co., D.C., conducted in-depth exchanges and discussions on the background of sulfate shuxinin research, test program, GCP key points, drug and project management, safety reporting process, medical supervision and program deviation.
Yangzhou Zhongbao Pharmaceutical Co., Ltd. Yangzhou Zhongbao Pharmaceutical Co., Ltd. is a comprehensive and innovative pharmaceutical enterprise featuring cardiovascular and chronic respiratory disease treatment drugs, is one of the first enterprises to build an integrated production line of BFS.
Zhongbao Pharmaceuticals has always been the source of research and development innovation as the source of enterprise development, is committed to become a high-quality pioneering small molecular drugs featuring the practice of science and technology, to provide patients with high-quality slow disease management services for the mission, in building an independent innovation research and development team on the basis of continuous improvement of the "imitation combination" of drug research and development system.
2018, Zhongbao Pharmaceuticals established the Nanjing Genesis Research Institute, the same year completed the sulfate Shuxin ii clinical trial work.
present, Zhongbao Pharmaceuticals has more than 30 varieties of pharmaceutical research, including 3 innovative drugs in progress, 12 inhalation preparations, 6 specialty eye drops and a number of high clinical value generic drugs.
"We hope to take five years to start and complete the layout from the sub-area of anti-arrhythmic disorder, and finally form a closed-loop mode of 'diagnostic screening, drugs, instruments, insurance and platform' to provide a full range of slow disease management platform services for patients with arrhythmic disorders."
, " stressed Zhang Guanya, chairman of Zhongbao Pharmaceuticals.
。